Johnson & amp; Johnson’s vaccine approved for emergency use in India, becomes the fifth vaccine to get approval

Johnsons & Johnsons Vaccine

On Saturday, Johnson & Johnson, an American vaccine manufacturer, has obtained significant authorization. The company’s single-dose vaccine has been approved for emergency use in India. The Union Minister for Health & Family Welfare, Mansukh Mandaviya, has provided this information via Twitter.

On Friday, Johnson & Johnson had sought permission from the Indian government for the emergency use of its vaccine. Significantly, this vaccine is a single-dose vaccine i.e. the vaccine’s one shot is sufficient to prevent COVID-19. Notably, the vaccines which are being administered in India currently are all double-dose vaccines.

After receiving the clearance, Johnson & Johnson’s spokesman in India said that the company is pleased after obtaining approval from the Government of India to use the vaccine in an emergency. The vaccine is approved to prevent COVID-19 in people above 18 years of age. Before this Johnson & Johnson’s vaccine, Bharat Biotech’s Covaxin, Serum Institute of India’s Covishield, Russia’s Sputnik-V, and Moderna COVID-19 vaccine were approved in India. Now, a total of five vaccines have been approved by the country to fight the COVID-19 pandemic.

Recently, the central government informed that the number of vaccinated people within the country has crossed 50 crores. On this achievement, the Minister of State in the Ministry of Health and Family Welfare, Bharti Pravin Pawar said that everyone should be proud that more than 50 crore doses of vaccine have been administered in the country within a short period. She further said that the government is making consistent efforts to ensure that the vaccines reach everyone. She also thanked the media and said that the role played by the media in this campaign is commendable. She added that initially, around 2.5 lakh vaccines were produced per day. Today, it has increased to about 40 lakhs per day which is quite respectable.

Related posts